Background: A phase I dose-escalation study of a new formulation of oral vinorelbine was conducted to determine the maximum tolerated dose (MTD) of a once weekly regimen and preliminary pharmacokinetic profile in patients with advanced breast cancer (ABC). Twenty-six patients were treated at dose levels ranging from 60 to 100 mg/m 2 /week. Pharmacokinetics was assessed during the first administration.
Background
Vinorelbine (Navelbine®) is a semisynthetic vinca-alkaloid that was first synthesised in 1978. It differs from other vinca-alkaloids in that structural modifications are on the catharantine ring instead of the vindoline ring. Vinorelbine induces cytotoxicity by binding to tubulin and inhibiting microtubule assembly. The toxicities of intravenously administered vinorelbine have generally been predictable and manageable and include neutropenia, moderate nausea and vomiting, neurotoxicity and minimal hair loss. Significant activity has been reported in advanced breast cancer (ABC) [1, 2] and advanced/ metastatic non small cell lung cancer (NSCLC) [3] [4] [5] .
The development of an oral formulation of vinorelbine had started in 1987. Two pharmaceutical forms were initially developed, a powder-filled capsule and a soft gelatine capsule formulation. Clinical studies of the soft gelatine capsule carried out by Rowinski et al. [6] have demonstrated an acceptable toxicological and pharmacological profile in a phase I study, and an activity comparable to intravenous vinorelbine in NSCLC [7] and in ABC [8] . Pharmacokinetics was described in plasma at a fixed dose of 80 mg/m 2 in different conditions of administration. However, those two pharmaceutical forms were abandoned because of stability problems. These clinical findings have driven the development of a new soft gelatine capsule formulation, the stability of which has now exceeded 24 months. The development of an oral formulation has been driven by the fact that i.v. lines are a major source of discomfort and stress to patients. Patient's preference [9] and cost savings are additional advantages of oral chemotherapy. A phase I study was carried out in patients with ABC in order to obtain early evidence of activity. The principal objective of this phase I study was to determine the maximum tolerated dose (MTD) of oral vinorelbine given once weekly and to select a dose for further clinical trials. Secondary study objectives were the tumour response in ABC and the pharmacokinetics of the drug. Since vinorelbine was demonstrated to highly bind to blood platelets and cells [21] , pharmacokinetics was performed on plasma and whole blood, the latter being more representative on this occasion.
Patients and methods

Patient selection
This study was initiated in November 1994 and closed to accrual on January 1996. Five centres participated.
All enrolled patients had histologically confirmed locally advanced or metastatic breast cancer and had received no more than two prior chemotherapy regimens for ABC. Other eligibility criteria included age over 18 years; Karnofsky performance status of 70% or greater; life expectancy of at least three months; a three-week minimum interval between the end of previous chemotherapy and study entry (six weeks for prior nitrosourea and mitomycin C); adequate haematopoietic function (haemoglobin ^ 9 g/dl, neutrophil count ^ 2000/mm J , and platelet count ^ lOO.OOO/mm 3 ); adequate liver function tests (total bilirubin < 2 mg/dl. transaminases < 2 x upper normal limit (UNL)); serum creatinine < 2.5 mg/dl and written informed consent.
Exclusion criteria included previous therapy with vinca-alkaloids. any unstable pre-existing major medical condition; previous radiotherapy involving > 25% of bone marrow; pregnant or lactating women; evidence of central nervous system metastases; pre-existing clinically significant peripheral neuropathy; malabsorption syndrome or disease affecting the gastrointestinal tract function, previous surgical resection of stomach or small bowel; or any psychological, family, sociological or geographical conditions hampering medical follow-up or compliance with the study protocol.
Study drug administration
Oral vinorelbine was supplied as soft gelatine capsules by Pierre Fabre Medicament in two dose strengths (30 and 40 mg). Oral formulation consisted of soft gelatine capsules filled with vinorelbine tartrate in a solution ethanol/water/glycerol/macrogol 400. This formulation which differed qualitatively and quantitatively from previously tested formulations by the solvent composition, allowed a better stability and shelf-life to be obtained. It was administered orally to fasted patients once weekly, swallowed with water. Individual doses were rounded to the nearest 10 mg. Patients were seen weekly and toxicity was assessed using the CALGB expanded common toxicity criteria (CALGB/expanded CTC)
The MTD was defined as the dose, when administered for the first four weeks, that causes dose-limiting toxicity in more than 50% of the patients treated (i.e. more than three out of a six-patient cohort). Doselimiting toxicity was defined as CALGB/expanded CTC grade 4 haematotoxicity or grade 5= 3 non haematological toxicity The recommended dose (RD) for further testing was considered as the dose level below the MTD.
There was no dose modification. On the day of treatment, neutrophils had to be > 1000/ul and platelets ^ 75,000 ul. Oral vinorelbine administration was delayed by one week up to three weeks until resolution for grade < 2 toxicity. If treatment delay exceeded three weeks, oral vinorelbine was discontinued.
A former study was performed with an intermediate drug formulation [6] . The recommended dose was initially defined at 100 mg/trr. Consequently, considering possible improvement of oral bioavailability of the new formulation, an initial dose of 60 mg/m 2 was selected, followed by a rapid increase of dose by 20 mg/m 2 steps. Six patients were to be treated at each dose level. If the MTD was not reached after 4 administrations at the first dose level, the next six patients were entered at higher dose-level. Once the RD was determined, six additional patients had to be treated at this dose level.
Pre-treatment and follow-up studies
Physical examination and routine laboratory tests were performed and Karnofsky performance status was determined at baseline. Complete blood cell (CBC) count, differential white blood cell (WBC) count were obtained weekly before oral dosing. Electrolytes, glucose, uric acid. calcium, urea, creatinine, creatinine clearance, total bilirubin, alkaline phosphatase, transaminases and LDH had to be repeated every four weeks.
Toxicities were evaluated according to the CALGB expanded CTC criteria. Tumour measurements were performed at baseline and every eight weeks. Response was assessed using standard World Health Organization (WHO) response criteria [10] . Complete response (CR) was defined as the complete disappearance of any evidence of disease for at least four weeks without appearance of new lesions. A partial response required at least a 50% reduction in the sum of the products of all measurable lesions for at least four weeks without appearance of new lesions.
Pharmacokinetics
Blood sampling and bioanalysis
Pharmacokinetic data were collected during the first course only. Venous blood samples (5 ml) for pharmacokinetic analysis were withdrawn into heparinized glass tubes immediately before and then 30 minutes. 1. 3, 8. 12 . 24 and 48 hours after the first dose of oral vinorelbine only. One ml of total blood was stored at -20 °C. The remaining blood was immediately centrifuged for 10 minutes (3000 r.p.m at 10 °C) and the plasma samples stored at -20 °C. Vinorelbine plasma and blood concentrations were quantified by high performance liquid chromatography (HPLC). The same method allowed the simultaneous determination of 4-O-deacetyl-vinorelbine. a metabolite of vinorelbine.
Briefly, vinorelbine and 4-O-deacetyl-vinorelbine were extracted from biological fluids (1 ml) with diethylether in alcaline conditions together with vinblastine. used as internal standard. Then, the organic phase was back-extracted by a pH = 3 buffered aqueous solution. An aliquot of this acidic phase was injected in a reversed phase cyano HPLC column. Ultraviolet detection was performed at 268 nm.
Using these conditions, the calibration curves ranged between 2.5 and 200 ngmF 1 for both compounds in plasma and blood. The method was validated with a limit of quantitalion of 2.5 ng-ml" 1 . Spiked controls were analysed with the unknown samples. The precision and accuracy were, respectively, higher than 90 % and 94 % for both compounds in plasma and blood.
Data analysis
Blood and plasma levels of vinorelbine and 4-O-deacetyl-vinorelbine were calculated using a model-independent approach with PHARM-NCA software (SIMED, France). The observed area under the curve (AUC| asl ) was calculated using the linear trapezoidal rule. The terminal half-life (T|/ 2 ) was estimated using a log-linear regression of terminal phase concentrations vs. time. The observed peak concentration (C max ) and time to maximum concentration (T max ) were also determined. Additionally, the blood and plasma concentrations measured 24 hours after drug intake (C24h) were used in the pharmacokinetic/pharmacodynamic analysis of haemalological toxicity
Comparisons between dose levels of oral vinorelbine were performed on AUQ ai ,,/dose, C max /dose by a one-way analysis of variance or Wilcoxon test.
Patients with or without early vomiting were compared for AUQ M /dose and C mllx /dose using Student's Mest Early vomiting was defined as that which occurred within one to three hours after drug intake. This time was selected since it was considered that the absorption process should be completed within three hours (about two to three fold more than the T mav ), and vomiting thereafter could no longer influence absorption.
Pharmacokinetic/'pharmacodynamic (PK/PD) relationships
An analysis of the relationship between drug exposure and both non haematological and haematological toxicity after the first administration was undertaken. For haematological parameters, the variation of: polymorphonuclear leukocyte (PMN). white blood cell (WBC) and red blood cell (RBC) counts; platelets and haemoglobin (Hb) at day 8 were compared with day 0 (before dosing) and the linear relationship between these parameters and C max , AUCi ast and C 2 4h investigated. To evaluate the PK/PD relationships in the case of non haematological toxicities, patients were split in two groups of toxicity in order to obtain approximately the same number of patients in both groups. The two groups were, respectively: vomiting grade ^ 2 and vomiting grade < 2 ; nausea grade ^ 2 and nausea grade < 2; diarrhoea grade > 1 and diarrhoea grade = 0; constipation grade ^ 1 and constipation grade = 0. Comparisons of AUC| as , and C max between groups were performed using the Wilcoxon test and Student's r-test
Results
Patients
Characteristics of all 27 patients are listed in Table 1 . One patient was never treated. Another patient did not meet eligibility criteria because she had previously received four lines of chemotherapy for ABC. This patient received 18 administrations of oral vinorelbine at the dose of 80 mg/m 2 /week and was included in the analysis of safety and pharmacokinetics.
The median age of the population was 54.6 years; 96% were postmenopausal and 37% were oestrogen receptor-positive. The majority of patients (85%) had received prior chemotherapy: five in the neoadjuvant setting, six in the adjuvant setting and 19 (70%) for metastatic disease. Out of those 19 patients, 10 had received one line of chemotherapy; eight, two lines; and one (non eligible patient) four lines.
Sixty-seven percent of patients had at least two organs involved. The most common sites of metastatic disease were lymph nodes (37%), bone (33%), lung (30%) and liver (30%).
Drug delivery
Three dose levels of 60, 80 and 100 mg/m 2 /week were investigated. Because five of the six patients treated at 100 mg/m 2 /week experienced dose-limiting toxicities, dose escalation was stopped. As per protocol, seven additional patients were included at 80 mg/m 2 /week which was thought to be the RD. The number of patients treated per dose level, the number of administrations and treatment delays are listed in Table 2 .
The percentage of delayed administrations increased with the dose: 11% at 60 mg/m 2 /week, 23% at 80 mg/ m 2 /week and 38% (31% when excluding the two-day delay for patient convenience) at 100 mg/m /week. The main reason for dose delay (91%) was neutropenia for all dose levels. Other reasons included alteration of performance status, infection, mistake and patient convenience in one instance each.
Toxicity
Haematological and major non haematological toxicities in the first four administrations are depicted in Tables 3 and 4 , respectively. Two patients out of the seven treated at the first dose level of 60 mg/m 2 /week experienced dose-limiting toxicity: one patient developed grade 4 neutropenia, grade 3 constipation and grade 3 stomatitis after a single administration and another patient experienced grade 3 stomatitis following two administrations. At the second dose level of 80 mg/m 2 /week, three of six patients experienced grade 4 neutropenia following the second or third administration of oral vinorelbine.
The dose level of 100 mg/m 2 /week was defined as the MTD since five of the six patients developed DLTs following the first three administrations (grade 4 neutropenia in three patients associated with grade 3 constipation in one patient and grade 3 vomiting in another patient; grade 4 constipation in one patient; and grade 4 vomiting in the last patient).
To better define the pattern of toxicities at 80 mg/m 2 / week, seven other patients were treated at this dose level as per protocol. In addition, because oral vinorelbine 80 mg/m 2 /week had been well tolerated in the first six patients, four of the six patients initially treated at 100 mg/m 2 /week received further administrations at 80 mg/m 2 /week. In total, 17 patients received 247 administrations (mean number of 14.5). Haematological and main non haematological toxicities which were reported over the whole courses are depicted in Table 5 . The most frequent toxicities were neutropenia, nausea, vomiting, diarrhoea, constipation, neurosensory disorders which consisted of mild to moderate paresthesia and/or loss of deep tendon reflexes and alopecia. A significant proportion of patients developed grade 4 neutropenia (62 % of the 13 patients treated at 80 mg/m 2 /week and 75% of the four patients treated at 100 and then at 80 mg/m 2 /week). Only two patients experienced febrile neutropenia. Gastrointestinal disorders were frequently encountered but generally of mild to moderate intensity.
Constipation occurred in about half of patients but was severe in only two of them (one patient treated at 80 mg/rrr/week and one patient initially treated at 100 and then at 80 mg/nr/week).
Across all dose levels, six patients experienced at least one serious adverse event considered as being related to oral vinorelbine. At 60 mg/m 2 /week, one patient developed grade 3 constipation, grade 3 stomatitis associated with grade 4 neutropenia after a single administration. She totally recovered but discontinued treatment because of excessive toxicity. At the same dose level, another patient was hospitalised because of grade 3 stomatitis and poor general condition following two administrations. The treatment could be resumed after a two-week delay.
At 80 mg/m 2 /week, two patients experienced febrile neutropenia following 7 and 69 administrations, respec- tively. Full recovery was obtained after hospitalisation and intravenous antibiotic therapy. Oral vinorelbine treatment was reinstituted for one patient and discontinued for the other one due to disease progression. One patient developed grade 4 constipation following two weekly administrations of 100 mg/m 2 oral vinorelbine and discontinued treatment. Another patient experienced diffuse jaw pain after one administration which led to her hospitalisation. She discontinued treatment after two additional courses due to pain recurrence. No toxicity-related death was reported.
In total, four patients were withdrawn from treatment because of drug-related toxicity: one patient at 60 mg/ m 2 /week (detailed above), one at 80 mg/nr/week because of grade 4 constipation following a single admin- istration; and two patients at 100 mg/m 2 /week because (a) of grade 4 constipation in one patient and severe jaw pain in the other patient.
1
Pharmacokinetics
Pharmacokinetic samples were collected from the 26 patients treated out of the 27 included. Plasma and blood samples were missing at only 3 occasions out of 120. The absorption of oral vinorelbine was rapid, with individual peak blood or plasma concentrations observed between 30 minutes and three hours after administration. At the RD of 80 mg/m 2 this resulted in a mean peak blood concentration (C max ) of 103.8 ± 41.6 ngmf' observed 1.2 ± 0.8 hours (T max ) after dosing. The metabolite 4-O-deacetyl-vinorelbine appeared slowly in blood, with a C max of 5.7 ± 2.4 ng • ml~' observed 6.4 ±3.1 hours (Tmax) after oral administration of 80 mg/m 2 . Vinorelbine concentrations in blood were higher but parallel to plasma concentrations (Figure 1 ). In fact, concentrations of both vinorelbine and 4-O-deacetylvinorelbine were higher in blood than in plasma and could be measured in most patients for longer sampling times in blood (48 hours at all dose levels) than in plasma (12-24 hours depending on dose level).
The main pharmacokinetic parameters were calculated for each dose level (Table 6 ). Terminal half-lives were about 12-15 h. These values are shorter than the usual range reported due to the 48 h time period of blood collection.
Comparisons of blood with plasma ratios of C max and AUCi ast showed no significant difference between dose levels, indicating that vinorelbine distribution is unaffected by dose levels between 60,80 and 100 mg/m 2 . C max and AUC were dose-adjusted (i.e. C max /dose and AUC/dose) and compared between groups through an ANOVA analysis. No statistical difference was observed, suggesting a dose proportional increase of those parameters (Table 7 , Figure 2 ). The influence of vomiting on the bioavailability of Abbreviation, n.c. -not calculated (below the limit of quantification for four patients out of seven). Relationships between VRL dose adjusted C max (a) and (b) and administered dose (solid line = blood, dotted line = oral vinorelbine was evaluated. Seven out of 26 patients vomited within the three hours following the drug intake and 19 out of 26 did not.
The comparison of C max /dose and AUCi ast / dose and T max in both blood and plasma showed no difference between the two groups of patients: those having and those having not experienced early vomiting. This lack of difference suggests that early vomiting (between 1 h and 3 h after drug intake) did not affect the absorption of vinorelbine.
Pharmacokinetic/'pharmacodynamic relationships
A limited analysis of the relationship between drug exposure and both non haematological and haematological toxicity was performed.
For haematological toxicities, AUC, ast and C 2 4h, but not C max , were correlated to the occurrence of leucopenia and neutropenia with negative, significant relationships found for WBC and PMN (Figure 3) . No relationship was found between most pharmacokinetic parameters and variation in RBC, platelets and haemoglobin levels between day 0 and day 8.
No relationship was found between pharmacokinetic parameters and occurrence of grade ^ 2 vomiting and nausea or grade > 1 diarrhoea. A statistically significant difference was observed between AUCi as , (P < 0.01) and C max (P < 0.05) of patients who experienced mild to severe (grade 1-4) constipation as compared with patients who did not. Mean parameters were AUC| ast = 1135hngmr' (C max = 162 ng-ml~') vs. 624 h-ng-ml" reported in the two evaluable patients who were given 80 mg/m 2 /week after one or two initial administrations at 100 mg/m 2 /week. Of note no response was observed in the six evaluable patients treated at 60 mg/m 2 /week. As shown in Table 8 , four of the six responders had previously received.at least one anthracycline containing regimen for the treatment of ABC. Three of the six responders had visceral disease. Duration of response ranged from 21 to 98 weeks. Out of the 19 patients treated at doses of 80 mg/m 2 /week or greater the response rate was 32% (95% confidence interval (95% CI): 11% to 52%).
Discussion
The objective of this phase I study was to evaluate the safety and pharmacokinetics of a new stable soft gelatine capsule formulation of oral vinorelbine. By recruiting patients with advanced breast cancer, preliminary evidence of activity was sought.
When administered once weekly, the MTD of oral vinorelbine was established to be 100 mg/m 2 /week due to the occurrence of dose-limiting neutropenia, nausea/ vomiting and/or constipation. At a lower dose level of 80 mg/m 2 /week the toxicity profile was manageable and consistent with the one of intravenous vinorelbine. The major toxicity was neutropenia: 77% of patients developed at least one episode of grade 3 or 4 neutropenia. By comparison, 69% to 80% of ABC patients experienced grade 3 or 4 neutropenia when treated with intravenous vinorelbine 30 mg/m 2 /week [1, 2, 11, 12] . Grade 4 neutropenia was associated with fever in 2 of the 17 (12%) patients who received 80 mg/m 2 /week initially or after one or two administrations at 100 mg/m 2 . Therefore weekly monitoring of blood counts and medical supervision of patients before each drug intake are necessary as it is the rule for intravenous vinorelbine. Gastrointestinal disorders, i.e. nausea, vomiting and diarrhoea appeared to be more frequently seen with oral vinorelbine than with the intravenous formulation. However, they were generally of mild to moderate intensity. Their incidence may be reduced by prophylactic treatment with antiemetics. Neurotoxicity was comparable for oral and intravenous vinorelbine, constipation due to autonomic neuropathy being the only dose-limiting toxicity. The significant relationship observed between constipation and AUQast suggests that this dose-limiting toxicity is more related to the body exposure to the drug than to the route of administration. Oral administration of vinorelbine eliminates injection site reactions and local phlebitis which were reported in some patients [4] following intravenous infusion.
The pharmacokinetic profile of oral vinorelbine evaluated during the first course of the study gave interesting preliminary information on the pharmacokinetics of the drug and their relationship with safety, despite the small number of samples withdrawn. They represent the first pharmacokinetic profiles in blood which is more relevant than plasma since vinorelbine is highly bound to platelets [20] . Concentrations were about twice higher in blood than in plasma as reflected by the average values of AUCi asl and C max in both medium, as reported in Table 6 . Vinorelbine was rapidly absorbed, with a C max of 103.8 ± 41.6 rig-ml" 1 observed 1.2 ± 0.8 hours (T ma ' x ) after oral administration at 80 mg/m 2 , which is the recommended dose for clinics. In the present study, the best approach to evaluate dose proportional increase of blood exposure (AUC) is generally to compare data on an intra-patient basis. However, such a design is ethically questionable for anticancer drugs. Moreover, the highest dose determined to be the MTD during the dose escalation study will never be administered again in further studies. Therefore, despite the lack of strength of the parallel group design in the assessment of the pharmacokinetic linearity, it nevertheless represents a unique opportunity to explore a wide range of doses. Pharmacokinetic linearity was strongly suggested between the oral doses of 60 to 100 mg/m 2 . Inter-patient variability on body exposure appeared higher after administration of 60 mg/m 2 (CV = 76 %) and 100 mg/m 2 (CV = 58%) than after administration of 80 mg/m 2 . Those discrepancies could be due to the reduced number of patients at level 60 (n = 7) and 100 (n = 6), the estimation being more precise at 80 mg/m 2 (CV = 32%; n -13). This inter-patient variability at the recommended oral dose is comparable to the one observed after i.v. administration [6] .
No relationship was found between pharmacokinetic parameters and the slight variation of red blood cells and platelets counts or haemoglobin levels, between day 0 and day 8. In contrast, significant relationships were found between AUCi ast and C 2 4h, but not C max , and depletion of white blood cells and granulocytes, demonstrating that these pharmacokinetic parameters can be correlated with the occurrence of leucopenia and neutropenia (the major DLT). The parameter C 2 4h was chosen on the assumption that at 24 hours, when the absorption phase is finished and the elimination phase is ongoing, C 24 h could well be correlated to drug body exposure. If relevant, this parameter could be useful to further studies where only one sample could be collected, in order to anticipate putative haematological toxicities in individual patients Six of the 14 evaluable patients who received the weekly dose of either 80 mg/m" or higher responded. Four of these patients had previously been treated with a prior anthracycline-containing regimen or docetaxel for locally advanced or metastatic disease. This activity seems consistent with the efficacy reported for intravenous vinorelbine 30 mg/m 2 /week as a single agent. Response rates ranging from 35% to 59% [11] [12] [13] [14] [15] [16] [17] and from 20% to 30% [18] [19] [20] were achieved in first line patients and second-line patients, respectively.
In summary, this phase I study on a new stable formulation of oral vinorelbine defined 80 mg/m" as the recommended weekly dose for further phase II studies. Dose proportional increase in vinorelbine blood exposure was observed and PK/PD relationship on haematological toxicity was demonstrated. The safety profile of oral vinorelbine 80 mg/m 2 /week appears to be comparable to the one of intravenous vinorelbine and justifies the same clinical monitoring. The anti-tumour activity of oral vinorelbine observed in first and second-line patients with advanced breast cancer appears also comparable to the activity of the intravenous form. Increased attention to patient convenience and preference and to pharmacoeconomic issues justifies further clinical development of this oral formulation.
